triple-negative breast cancer (TNBC;BRCA1), oestrogen receptor (ER)-positive breast cancer (BC), and human epidermal growth factor receptor 2 (HER2)-negative BC (BRCA2); however, all BC subtypes can occur in association with g
针对前者患者人群,BRCA1/2基因检测具备两方面功能:一方面为患者提供用药指导提示;二方面为患者的预后提供监测作用,方便患者在预后过程中采取对应的管理方案。针对后者健康人群,产品主要对于高危健康人群起预防功能。家族中如有乳腺癌或/和妇科肿...
BRCA2Cancer: breastsurvivorshipBackground For patients with early breast cancer, knowledge of germline BRCA1 / 2 status increasingly influences management as well as informing future cancer risk for patients and their families. As access to germline testing expands, it is important that this benefit ...
In hopes that won't happen, many women are choosing to be tested for what's been called the “breast cancer gene” — BRCA. Mutations of the BRCA1 and BRCA2 genes can significantly increase the risk of developing cancer. Expert panel updates advice on breast cancer BRCA gene screening The...
乳腺癌的BRCA基因来自 BReast CAncer的缩写,400 人中有 1 人天生带有突变的 BRCA1 或 BRCA2 基因。有统计发现,到 80 岁时,72% 携带有缺陷 BRCA1 基因的女性会患乳腺癌,44% 会患卵巢癌。 同样,80岁时, 携带 BRCA2 基因的女性69%会患乳腺癌,17% 会患卵巢癌。 û收藏 19 20 ...
Identification ofBRCAmutations in breast cancer (BC) patients influences treatment and survival and may be of importance for their relatives. Testing is often restricted to women fulfilling high-risk criteria. However, there is limited knowledge of the sensitivity of such a strategy, and of the cli...
Carrying a BRCA1/2 gene mutation increases one's life- time risk of developing breast and/or ovarian cancer compared with the general population.1 The most noted benefits of test- ing for mutations are: (1) to obtain breast cancer risk informa- tion for one's self and family members, ...
Who qualifies for BRCA testing? Overall,inheritedbreastcancerdisorders account for a small minority of breast cancers. Genes are the "messages" in each cell of the body that determine the ultimate design of our bodies. Genes can be damaged by the environment. Additionally, people can be born wi...
Genes such as breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2), or mutations or variants in other genes First monthly period before age 12, or menopause that starts after age 55 Long-term use of estrogen or progestin, or exposure to chest or face radiation before the age of 30 Firs...
Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Trust, Southampton SO16 6YD, UK; 7Breakthrough Breast Cancer Research Unit, King's College, London SE1 9RT, UK BACKGROUND: Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation...